Shiu-Feng Kathy Huang, M.D., Ph.D.
Investigator and attending physician
Institute of Molecular and Genomic Medicine
sfhuang@nhri.edu.tw
Office: 037-206-166, extension 35315
Lab: 037-206-166, extension 35316
Fax: 037-586-459
EDUCATION
M.D. (1975-1983): College of Medicine, National Taiwan University
Ph.D. (1989-1997): Institute of Pathology, College of Medicine, National Taiwan University
TRAININGS AND EXPERIENCES
2010– present Investigator and attending physician, Institute of Molecular and Genomic Medicine, National Health Research Institutes
2007– present Director of Pathology Core Laboratory, National Health Research Institutes
2010– present Adjunct Professor, Department of Pathology, Tzu-Chi University School of Medicine
2003—present Adjunct attending physician, Department of Pathology, Chang-Gung Memorial Hospital, Linko, Taoyuan
2003– 2010 Associate investigator and attending physician, Division of Molecular and Genomic Medicine, National Health Research Institutes
2008– 2010 Adjunct Associate professor, Department of Pathology, Tzhu-Chi University School of Medicine
2003– 2008 Adjunct Associate professor, Department of Pathology, Taipei Medical University School of Medicine
2000– 2003 Associate professor of Pathology, Chang-Gung University School of Medicine
2000– 2002 Director of Anatomical Pathology, Department of Pathology, Chang- Gung Memorial Hospital, Linko
1999– 2003 Attending physician, Department of Pathology, Chang-Gung Memorial Hospital, Linko, Taoyuan
1989– 1999 Instructor, Department of Pathology, College of Medicine, National Taiwan University
1989– 1999 Attending physician, Department of Pathology, National Taiwan University Hospital, Taipei, Taiwan
1994– 1995 Research fellow, Department of Pathology, Brigham and Women’s Hospital & Harvard Medical School, U.S.A
1990– 1991 Clinical fellow, Department of Pathology, Children’s Hospital in Boston & Harvard Medical School, U.S.A
1987– 1989 Chief resident, Department of Pathology, National Taiwan University Hospital
1987– 1989 Teaching Assistant, Department of Pathology, College of Medicine, National Taiwan University , Taipei, Taiwan
1984– 1987 First year to third year resident, Department of Pathology, Chang-Gung Memorial Hospital, Taipei, Taiwan.
1983– 1984 First year resident, Department of Pediatrics, Chang-Gung Memorial Hospital, Taipei, Taiwan.
BOARD CERTIFICATION
1983 National Certification Examination for medical graduates, Taiwan
1983 Educational Commission for Foreign Medical Graduates (ECFMG), U.S.A.
1983 Visa Qualifying Examination (VQE), U.S.A.
1988 Board Certification Examination for Anatomical Pathology, Taiwan
MEMBERSHIP IN SCIENTIFIC SOCIETIES
Taiwan Pathological Society
Formosan Medical Association
The Chinese Oncology Society
Society of Pediatric Pathology
Taiwan Association for the study of the liver (TASL)
AWARDS
1981 Professor Shu Yeh’s Award for Best Performance in Pathology (medical student)
1993 Best Teacher Award (National Taiwan University College of Medicine)
1998 Professor Shu Yeh’s Award for Best Performance in Pathology (graduate student)
1998 Award for excellence in teaching (National Taiwan University Hospital)
1998 Best Teacher Award (National Taiwan University College of Medicine)
1999 Award for excellence in teaching (National Taiwan University)
2000 Best Research Award of National Science Council of Republic of China
2005 Professor Shu Yeh’s Award for Best Paper in Pathology
RESEARCH INTERESTS
Dr. Huang is an experienced senior pathologist, especially in lung, liver and pediatric pathology. She has up to 220 publications so far. Dr. Huang’s research interests are biobank establishment and molecular genetic studies related to tumorigenesis of solid tumors, mainly focusing on hepatocellular carcinoma and lung cancers. She also has expertise in diagnostic molecular pathology, focusing on molecular diagnostic biomarker in solid cancers and pediatric tumors.
HIGHLIGHTS OF RECENT RESEARCH
Dr. Huang’s research team was the first research team in Asia to publish a high EGFR mutation rate in non-small cell lung cancer (NSCLC) patients in 2004, which is related to the responsiveness of gefitinib, an EGFR tyrosine kinase inhibitor. This important finding suggest that Taiwanese lung cancer patients would have higher response rate to this new drug and will have benefit in prolonged survival. In the following years, her research team has published more than twenty EGFR mutation or TKI-related papers of NSCLC.
Dr. Huang is also the key person that helps to establish the largest and the best liver cancer biobank in Taiwan and the world with biosamples of more than 9,000 liver tumor patients (Taiwan Liver Cancer Network). This biobank has become the most important resource for all liver cancer researchers in Taiwan. This large liver cancer biobank is belonged to NHRI Biobank now. NHRI Biobank also recruits more than 2,000 lung cancer patients. Dr. Huang is the current Biomedical Director of NHRI Biobank. In 2016 and 2018, her research team published two important paper about a detailed viral marker study on 3,843 HCC patients collected in Taiwan Liver Cancer Network and a 411 NBNC HCC series, which are both the largest detailed HCC study series in the literatures.
Dr. Huang’s research team also have studied a lot on the HBV-related hepatocarcinogenesis. In Taiwan, hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) patients have a very high frequency HBV mutations. Those mutations may play an important role in hepatocarcinogenesis. By xenograft animal study, we already found three nonsense mutations of hepatitis B virus S (HBS) gene have oncogenic activity, especially sW182 non-sense mutant. sW182 non-sense mutation is also the most common non-sense mutation found in the HCC tumor tissues. We will use an in vivo animal approach to achieve the sW182* long-term expression in the mouse hepatocytes by hydrodynamic injection combined with Sleeping Beauty transposase mediated somatic integration. The sW182 non-sense mutant will be expressed in this animal model alone or in combination with host factors or environment factors to investigate their synergistic effects in promoting hepatocarcinogenesis in vivo.
SELECTED PUBLICATIONS ( 10 out of 202 papers)
liver cancers:
1. Huang SF (corresponding author), Hsu HC, Fletcher JA. Investigation of chromosomal aberrations in hepatocellular carcinoma by fluorescence in situ hybridization. Cancer Genet Cytogenet 1999;111:21-27.
2. Huang SF (corresponding author), Hsu HC, Chen JC, Chie WC, Lai PL.Tetrasomy 6 and 6q14 deletion are associated with better survival in hepatocellular carcinomas:: a fluorescence in situ hybridization study of 77 cases. Cancer Genet Cytogenet 2003 July;144:23-30.
3. Shiu-Feng Huang (corresponding author), Ya-Ting Chen, Wei-Chen Lee, Il-Chi Chang, Yu-Ting Chiu, Yu Chang, Hsiao-Chen Tu, Chiou-Hwa Yuh, Isao Matsuura, Liang-Yu Shih, Ming-Wei Lai, Hong-Dar Isaac Wu, Miin-Fu Chen, Chau-Ting Yeh. Identification of transforming hepatitis B virus S gene nonsense mutations derived from freely replicative viruses in hepatocellular carcinoma. PLoS ONE 2014, Feb.25; 9(2): e89753. doi:10.1371/journal.pone.0089753.
4. Shih Sheng Jiang*, Shiu-Feng Huang*(*equal contribution), Min-Syuan Huang, Yng-Tay Chen, Hsiang-Ju Jhong, Il-Chi Chang, Ya-Ting Chen, Jer-Wei Chang, Wen-Ling Chen, Wei-Chen Lee, Miin-Fu Chen, Chau-Ting Yeh, Isao Matsuura. Dysregulation of the TGFBI gene is involved in the oncogenic activity of the nonsense mutation of hepatitis B virus surface gene sW182*. Biochim Biophys Acta-molecular basis of disease. Biochimica et biophysica acta –molecular basis of disease (BBA-MBD), 2014, July, 1842(7):1080-1087. [Epub ahead of print on 2014 Mar 22.]
5. Shiu-Feng Huang (corresponding author), Hong-Dar Isaac Wu, Ya-Ting Chen, Saravana R. K. Murthy, Yu-Ting Chiu, Yu-Chang, Xuyu Yang, Il-Chi Chang, Y. Peng Loh. Carboxypeptidase E is a prediction marker for tumor recurrence in the early stage hepatocellular carcinoma. Tumor Biology 2016, Jan. 23, published online. Doi: 10.1007/s13277-016-4814-7.
6. Il-Chi Chang, PhD.,Shiu-Feng Huang, MD.,PhD.(corresponding author), Pei-Jer Chen, MD.,PhD.,Chi-Ling Chen, PhD.,Chao-Long Chen, MD.,Cheng-Chung Wu, MD., Cheng-Chung Tsai, MD.,Po-Huang Lee, MD., Miin-Fu Chen, MD., Chuan-Mo Lee, MD., Hsien-Chung Yu, MD., Gin-Ho Lo, MD., Chau-Ting Yeh, MD.,PhD., Chih-Chen Hong, PhD., Hock-Liew Eng, MD., John Wang, MD., Hui-Hwa Tseng, MD., Cheng-Hsiang Hsiao, MD., Hong-Dar Isaac Wu, PhD., Tseng-Chang Yen, PhD., Yun-Fan Liaw MD. The hepatitis viral status in patients with hepatocellular carcinoma – a study of 3843 patients from Taiwan Liver Cancer Network. Medicine (Baltimore) 2016 Apr;95(15):e3284. April 17.
Lung cancers:
7. Huang SF, Liu HP, Li LH, Ku YC, Fu YN, Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, Wu YC, Chen YR, Tsai SF. High Frequency of EGFR mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clinical Cancer Research 2004;10(24):8195-203.
8. Chen YR, Fu YN, Lin CH, Yang ST, Hu SF, Chen YT, Tsai SF, Huang SF (Corresponding author). Distinctive Activation Patterns in Constitutively Active and Gefitinib-Sensitive EGFR Mutants. Oncogene 2006 Feb 23, 25:1205-1215, Epub 2005,Oct.3
9. Hsieh MH, Fang YF, Chang WC, Kuo HP, Lin SY, Liu HP, Liu CL, Chen HC, Ku YC, Chen YT, Chang YH, Chen YT, Hsi BL, Tsai SF, Huang SF (corresponding author). Complex Mutation Patterns of Epidermal Growth Factor Receptor Gene Associated with Variable Responses to Gefitinib Treatment in Patients with Non-Small Cell Lung Cancer. Lung Cancer 2006; Sep. 53:311-322, Epub 2006, Jul 24.
10. Chang JW-C, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF (corresponding author). Increased Epidermal Growth Factor Receptor (EGFR) Gene Copy Number is Strongly Associated with EGFR Mutations and Adenocarcinoma in Non-Small Cell Lung Cancers: A Chromogenic in situ Hybridization Study of 182 patients. Lung Cancer 2008, September;61:328 -339.
11.Wu CC, Hsu HY, Liu HP, Chang JWH, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF (corresponding author). Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of lung in Taiwan and its implication. Cancer, 2008 Dec 1;113(11):3199-208.
12. Liu Hp, Wu HD, Chang JWH, Wu YC, Yang HY, Chen YT, Hsieh WY, Chen YT, Chen YR, Huang SF (corresponding author). Prognostic implications of EGFR and KRAS gene mutations, and EGFR gene copy numbers in Surgically Resectable Non-Small Cell Lung Cancer Patients in Taiwan. J Thorac Oncol 2010;5:1175-1184.
13. Chen YT, Liu Hp, Chang JWH, Wu YC, Yu TF, Hsieh JJ, Chen YR, Huang SF (corresponding author). Clinical implications of high MET gene dosage in non-small cell lung cancer patients without prior tyrosine kinase inhibitor treatment. J Thorac Oncol 2011 Dec;6:2027- 2035.
14. Yi-Cheng Wu, MD, Il-Chi Chang, PhD, Chi-Liang Wang, MD, Tai-Di Chen, MD, Ya-Ting Chen, MS, Hui-Ping Liu, MD, Yen Chu, PhD. Yu-Ting Chiu, BS, Tzu-Hua Wu, MS, Li-Hui Chou, PhD, Yi-Rong Chen, PhD, Shiu-Feng Huang, MD, PhD. (corresponding author) Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan. PLoS ONE 2013 August 7, 8(8): Article number e70839. doi:10.1371/journal.pone.0070839.
15. Chi-Hwa Yang, Hsiao-Chin Chou, Yu-Ning Fu, Chi-Ling Yeh, Hui-Wen Cheng, Il-Chi Chang, Ko-Jiunn Liu, Gee-Chen Chang, Ting-Fen Tsai, Shih-Feng Tsai, Hui-Ping Liu, Yi-Cheng Wu, Ya-Ting Chen, Shiu-Feng Huang (corresponding author), Yi-Rong Chen. EGFR over-expression in non-small cell lung cancers harboring EGFR mutations is associated with marked down-regulation of CD82. Biochim Biophys Acta (BBA-MBD). 2015 Jul;1852(7):1540-9
Lab Members
